MedPath

Correlation of CA19-9 blood marker and ability to cure pancreatic cancer with surgery

Not Applicable
Conditions
Health Condition 1: C259- Malignant neoplasm of pancreas, unspecified
Registration Number
CTRI/2024/07/071305
Lead Sponsor
Dr Shrey Khanna
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Phase 1 -All patients diagnosed with pancreatic cancer above 18 years of age

Phase 2 -All Patients consenting to the study who are-

Patients newly diagnosed with pancreatic tumour based on CT/MRI Findings or Biopsy

Patients who are known case of pancreatic tumour presenting to the hospital for further management

Exclusion Criteria

Patients under 18 years of age

Neuroendocrine tumours of the pancreas

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
cutoff value of CA19-9 for resectability of pancreatic tumours.Timepoint: 2 years
Secondary Outcome Measures
NameTimeMethod
sensitivity and specificity of CA19-9 levels with resectability of pancreatic tumours.Timepoint: 2 years
© Copyright 2025. All Rights Reserved by MedPath